Managing blood sugar requires reliable tools, and for many people with diabetes, a continuous glucose monitor (CGM) has become one of the most important ones. But whether insurance covers a CGM, and under what conditions, depends heavily on the type of plan, the diagnosis, and how the claim is submitted.
This guide breaks down CGM coverage across Medicare, Medicaid, and major private insurers, explains how real-time glucose monitoring works within the US insurance system, and walks through what to do if a claim is denied.
At a Glance: CGM Insurance Coverage (2026)
| Topic | Key Facts |
|---|---|
| What is a CGM? | A wearable sensor that tracks glucose levels continuously through interstitial fluid |
| Who is typically covered? | People with diabetes using insulin; some non-insulin T2D and gestational diabetes patients qualify |
| Medicare coverage | Part B (DME); 20% co-insurance after deductible; expanded eligibility since April 2023 |
| Medicaid coverage | Varies by state; 48 states + D.C. offer some coverage as of 2024 |
| Private insurance | Most major plans cover CGMs for T1D; T2D coverage depends on insulin use |
| FSA/HSA eligible? | Yes, CGMs and sensors are FSA and HSA eligible |
| Prescription required? | Yes, a valid prescription is required for insurance reimbursement |
| What if denied? | Appeal is possible; about 40% of appealed ACA Marketplace claims are overturned (KFF, 2019 data) |
Does Insurance Cover a Continuous Glucose Monitor? Quick Answer
Most insurance plans cover continuous glucose monitoring for people with diabetes who use insulin, though specific rules differ by plan type.
Private insurers, Medicare, and most Medicaid programs recognize CGMs as covered medical equipment when prescribed for a qualifying diabetes diagnosis. Coverage is less consistent for people with type 2 diabetes who do not use insulin, and almost absent for prediabetes. The 2023 update to Medicare's CGM coverage criteria expanded access meaningfully, and similar progress is happening across state Medicaid programs.
The short answer: if insulin is part of a diabetes treatment plan, coverage is likely available. If not, it depends on the insurer and the clinical documentation provided.
Medicare CGM Coverage: 2026 Criteria (Who Qualifies)
Medicare covers CGMs under Part B as durable medical equipment (DME), which means the device must be prescribed by a physician and obtained through a Medicare-enrolled supplier.
In April 2023, the Centers for Medicare & Medicaid Services (CMS) updated its CGM coverage criteria. The previous requirement that patients document at least four daily fingerstick tests was removed. The update aligned Medicare's coverage rules with the American Diabetes Association's (ADA) 2025 Standards of Care in Diabetes, which recommend CGM for anyone with diabetes using insulin.
To qualify for Medicare CGM coverage in 2026, a patient must meet all four of the following criteria, as outlined in the AAFP's summary of the 2023 updates:
- Have a confirmed diagnosis of diabetes mellitus (type 1 or type 2, or gestational)
- Use insulin or have a documented history of problematic hypoglycemia (low blood sugar events)
- Have received CGM training, documented by the prescribing provider
- Have had an in-person or Medicare-approved telehealth visit with the prescriber within the six months before the CGM order
The removal of the fingerstick documentation requirement was particularly meaningful. As Anderson et al. noted in a 2020 PMC analysis, requiring four daily fingerstick tests as a precondition for CGM coverage was both inconsistent and clinically unjustified, given that Medicare only reimbursed three test strips per day for the same population.
What Medicare pays: After meeting the annual Part B deductible ($240 in 2024), Medicare covers 80% of the CGM cost. The patient is responsible for the remaining 20%. Those enrolled in a Medicare Advantage plan may have different cost-sharing arrangements.
Which CGM systems are covered: Currently, Medicare covers the Dexcom G6, Dexcom G7, FreeStyle Libre 14-day, FreeStyle Libre 2, and FreeStyle Libre 3. The device must include a durable, standalone receiver. CGM-only systems without a dedicated receiver (such as the Medtronic Guardian Connect used alone) do not meet Medicare's DME classification criteria.
Dual-eligible patients: People enrolled in both Medicare and Medicaid pay no out-of-pocket costs for covered CGM devices.
If a claim was denied before April 2023, reapplying is worth doing. The 2023 criteria update expanded eligibility meaningfully, and patients previously found ineligible may now qualify.
Medicaid & State-by-State CGM Coverage
Medicaid CGM coverage varies considerably from state to state, and what applies in one state may not apply in another.
As of 2024, 48 states and Washington, D.C. provide some CGM coverage for Medicaid beneficiaries. Alabama, Arizona, Florida, Georgia, Hawaii, Kansas, New Jersey, and the District of Columbia have limited or no CGM coverage for most Medicaid recipients with diabetes. State-level variation affects not just availability but also which diabetes types qualify and whether the device is accessible through a pharmacy benefit or a medical/DME benefit.
Twenty-nine states allow CGMs to be filled through the pharmacy benefit, which simplifies access significantly. Patients in those states can fill a sensor prescription at a local pharmacy, often with no out-of-pocket cost.
The most common Medicaid eligibility requirements across states include:
- A confirmed diabetes diagnosis
- Regular visits with an endocrinologist or qualifying diabetes care provider
- Evidence of self-monitoring (typically 3 or more fingerstick tests per day)
- Insulin use (required in most, but not all, states)
Some states have liberalized these requirements in recent years. To find out what coverage is available in a specific state, the ADCES CGM Insurance Coverage Lookup Tool allows users to search by insurer, plan type, and state.
People in a state with limited Medicaid CGM access who rely on at-home blood sugar management may benefit from exploring manufacturer assistance programs, described later in this guide.
Private Insurance: Aetna, Cigna, UnitedHealthcare & BCBS Breakdown
Most major private insurers cover CGMs for type 1 diabetes patients and for those with type 2 who use insulin. The details vary by insurer, plan tier, and state.
According to Abbott's cost and coverage data, FreeStyle Libre systems are covered by over 95% of private insurance plans, with most covered patients paying between $0 and $20 per month for sensors.
| Insurer | T1D Coverage | T2D Coverage | Notes |
|---|---|---|---|
| Aetna | Yes | Yes, on MDI or pump; not meeting glycemic targets OR experiencing hypoglycemia | Prior authorization typically required |
| Cigna | Yes | Typically requires insulin use; check individual plan | Coverage specifics vary by employer plan |
| UnitedHealthcare | Yes | Yes, for adults on insulin | Some plans route through pharmacy benefit |
| Blue Cross Blue Shield | Yes | Yes, for adults on insulin therapy | Coverage varies by state BCBS affiliate |
| Kaiser Permanente | Yes | Yes, for adults on MDI or insulin pump | Integrated delivery may simplify access |
Prior authorization: Most private insurers require prior authorization (PA) before covering a CGM. This is a formal review process in which the insurer evaluates whether the device is medically necessary. The prescribing provider's office typically handles PA submission, but patients should confirm the process with their insurer before the device is ordered.
Pharmacy vs. DME benefit: Whether a CGM is processed under the pharmacy benefit or the medical/DME benefit affects both out-of-pocket cost and the supplier used to obtain the device. Many insurers have shifted CGMs to the pharmacy benefit in recent years, allowing patients to fill prescriptions at retail pharmacies. If a plan processes CGMs as DME, the device must be obtained through an approved DME supplier. Getting clarity on which benefit applies before ordering prevents unexpected billing issues.
Will Insurance Cover CGM for Prediabetes or Type 2?
CGM coverage for type 2 diabetes without insulin use is limited, and coverage for prediabetes is almost universally unavailable through standard insurance benefits.
Type 2 diabetes with insulin: People with type 2 diabetes on multiple daily injections (MDI) or an insulin pump are covered by most major private insurers and by Medicare under the 2023 expanded criteria.
Type 2 diabetes without insulin: This is where coverage becomes more difficult. Medicare now covers CGMs for non-insulin-using patients who have a documented history of problematic hypoglycemia, but most commercial insurers still require insulin use as a baseline criterion. Anderson et al. noted in their PMC analysis that major private insurers including Anthem and Aetna do not extend CGM coverage to non-insulin-using type 2 patients under standard policy criteria.
For non-insulin type 2 patients seeking coverage, the most viable path is building a strong medical necessity case. Documentation of glucose variability, A1C trends, frequent hypoglycemic episodes, or a provider statement explaining why CGM data is clinically necessary to reduce the risk of long-term diabetes complications can support a coverage request or appeal.
Gestational diabetes: Most insurance plans will cover a CGM during pregnancy for gestational diabetes when prescribed, though eligibility criteria can be more restrictive. Coverage is more consistently available when insulin is part of the gestational diabetes treatment plan. Patients should confirm coverage before ordering to avoid unexpected out-of-pocket costs.
Prediabetes: Standard insurance benefits do not cover CGMs for prediabetes. A small number of employer-sponsored wellness programs include CGM access, and some patients use manufacturer cash-pay programs or direct purchase options (discussed in the next section).
CGM for Free: Manufacturer Programs, FSA/HSA & Discounts
Cost should not be the only barrier to access. Several programs exist to lower or eliminate out-of-pocket expenses for CGMs.
Manufacturer Patient Assistance Programs
Both Abbott and Dexcom offer direct financial support for patients who cannot afford CGM costs:
- Abbott FreeStyle Libre: According to Abbott's cost and coverage page, most commercially insured patients pay between $0 and $35 per month. Abbott also offers a savings program for uninsured cash-pay consumers.
- Dexcom: Most commercially insured users have a $0 copay. Dexcom offers a Patient Assistance Program for uninsured or underinsured patients facing financial constraints.
- Free CGM trials: Some manufacturers provide free trial sensors for patients who want to try a device before committing to a full prescription. Availability changes, so checking directly with the manufacturer is advisable.
- GoodRx: For patients without insurance coverage, GoodRx coupons can reduce the retail cost of CGM sensors at participating pharmacies.
FSA and HSA Eligibility
Continuous glucose monitors are eligible expenses under both flexible spending accounts (FSAs) and health savings accounts (HSAs). This includes the CGM device itself, replacement sensors, and related supplies.
FSA and HSA funds are contributed pre-tax, which effectively reduces the net cost of CGM supplies by the account holder's marginal tax rate. For patients with high-deductible health plans where insurance covers little until the deductible is met, FSA and HSA funds can meaningfully offset costs during the deductible period.
To use FSA or HSA funds, patients typically submit itemized receipts or a letter of medical necessity through their benefit account administrator. CGM sensors and transmitters purchased at a pharmacy are generally eligible without additional documentation.
Do You Need a Prescription? Getting CGM Covered Step by Step
A prescription is required for insurance to cover a continuous glucose monitor. Without one, the device may still be available for purchase, but at full retail cost and without reimbursement.
The step-by-step process for getting a CGM covered:
-
Speak with your provider. A prescribing physician, endocrinologist, nurse practitioner, or physician assistant with prescribing authority can order a CGM. The visit must be documented in the medical record with a diabetes diagnosis and the clinical rationale for CGM use.
-
Review your plan's formulary or DME list. Log into your insurer's member portal or call the member services number on your insurance card. Confirm whether CGMs are covered under the pharmacy benefit or medical/DME benefit, and whether prior authorization is required.
-
Confirm prior authorization requirements. If PA is required, the prescriber's office typically submits documentation including the diabetes diagnosis code, treatment history, and a letter of medical necessity.
-
Use the ADCES CGM Coverage Lookup Tool. The ADCES lookup tool allows searches by insurer, plan type, and state to get a current summary of coverage requirements.
-
Request a free benefits check from the manufacturer. Both Dexcom and Abbott offer free insurance benefits verification services. A representative from the company contacts the insurer directly to confirm coverage and co-pay amounts before a device is ordered.
-
Order through an approved supplier. If the device is processed as DME, it must come from an approved supplier. For pharmacy benefit coverage, standard retail pharmacies may be used.
What to Do If Your CGM Claim Is Denied
A denied claim is not necessarily a final answer. According to a KFF analysis of 2019 ACA Marketplace plan data, roughly 40% of insurance claim denials that are appealed internally are overturned. Understanding why a claim was denied is the first step toward reversing it.
5 Common Reasons CGM Claims Are Denied
-
Missing or incomplete documentation. The insurer needs proof of medical necessity. If the chart notes did not include insulin use history, documented hypoglycemia, or a clear clinical rationale, the claim may be rejected. The fix: ask the provider to submit updated documentation.
-
Routed through the wrong benefit. A CGM submitted as a pharmacy benefit claim may be denied if the insurer classifies it as DME, and vice versa. Confirming the correct benefit pathway before ordering prevents this.
-
Prior authorization not obtained. If the insurer required PA and it was not submitted before the device was dispensed, the claim will typically be denied. Always check PA requirements in advance.
-
Eligibility criteria not met (on file). If the medical record does not show insulin use or qualifying hypoglycemia episodes, the insurer may conclude the patient does not meet coverage criteria. Supplementing the record with glucose logs or a detailed provider letter can address this.
-
Incorrect billing codes. CGMs must be billed under the appropriate HCPCS code (E2103 for therapeutic CGMs under Medicare). Coding errors by a supplier are a correctable administrative issue.
How to File an Appeal
Under the Affordable Care Act (ACA), every insured patient has the right to an internal appeal with their insurer and, if that appeal is denied, an independent external review.
Steps for filing an appeal:
- Request the denial letter in writing if not already received. The letter must state the specific reason for denial.
- Review the insurer's Clinical Policy Bulletin (CPB) or Coverage Determination document, which lists the exact criteria the insurer uses. This is a formal document; ask for it in writing.
- Work with the prescribing provider to assemble supporting documentation: glucose logs, A1C history, records of hypoglycemic events, the ADA's published Standards of Care (which recommend CGM for all insulin-using patients), and a detailed letter of medical necessity.
- Submit the internal appeal by the deadline specified in the denial letter. Appeals cannot be filed by phone; written documentation is required and should be saved.
- If the internal appeal is denied, request an independent external review. External reviewers are unaffiliated with the insurer. Under the ACA, this right applies to most private plans.
Patients in employer-sponsored plans may also ask their HR department or benefits manager whether they can intervene directly with the insurer.
For patients who have exhausted coverage options, Momentary Lab's AI healthcare navigator can help clarify next steps based on individual insurance situations, and finding a doctor near you who specializes in diabetes management can strengthen the clinical documentation needed for an appeal.
Frequently Asked Questions
Does Medicare cover CGMs for non-insulin users? Yes, in some cases. Following the April 2023 CMS criteria update, Medicare now covers CGMs for patients with a documented history of problematic hypoglycemia, even if they do not use insulin. The patient must still meet the other eligibility requirements, including an in-person or telehealth visit within six months of the CGM order.
Is a continuous glucose monitor FSA eligible? Yes. CGMs, sensors, and related supplies are eligible expenses under both FSAs and HSAs.
Does insurance cover CGM for gestational diabetes? Most plans will cover a CGM for gestational diabetes when prescribed, though coverage criteria can vary. Plans that require insulin use as a prerequisite may deny coverage for gestational diabetes managed with diet and oral medication alone. Confirming coverage before ordering is advisable.
What is the cheapest way to get a CGM without insurance? Manufacturer savings programs, GoodRx coupons, and FSA/HSA funds are the primary cost-reduction options. Dexcom and Abbott both offer patient assistance programs for qualifying low-income patients. Free CGM trial programs are also periodically available directly from manufacturers.
Do you need a prescription for a continuous glucose monitor? Yes. A valid prescription from a licensed healthcare provider is required for insurance coverage of a CGM. Some CGM-adjacent wearables marketed for metabolic wellness do not require a prescription, but these are not the same as FDA-cleared therapeutic CGMs and are not covered by insurance.
